Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Among patients with stage IA non-small cell lung cancer, long-term survival was better with lobectomy or segmentectomy vs.

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

We must come together to combat air pollution and move to clean energy to prevent more needless deaths from lung cancer.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...